"Analyzing Market Sentiments: Pfizer and Illumina Face Downgrades Amid Patent and Rating Challenges"
TL;DR Summary
Pfizer Inc.'s stock was downgraded from outperform to market perform by TD Cowen due to concerns over upcoming patent expirations for major drugs and doubts about the company's management. Despite potential earnings growth, the loss of exclusivity for drugs like Eliquis and Ibrance is expected to impact the company's long-term performance. Analysts also questioned Pfizer's recent asset divestment decisions. The company's shares have seen a significant decline over the past year, contrasting with gains in the broader S&P 500 index.
Topics:business##business-and-finance#marketperformance#patentexpirations#pfizer#pharmaceuticals#stockdowngrade
- Pfizer shares downgraded as patent expirations loom MarketWatch
- Should You Think About Buying Illumina, Inc. (NASDAQ:ILMN) Now? Yahoo Finance
- Deep Dive Into Illumina Stock: Analyst Perspectives (9 Ratings) - Illumina (NASDAQ:ILMN) Benzinga
- Pfizer and Illumina downgraded but Merck can deliver, declares TD Cowen Investing.com India
- Illumina techs lean bullish despite TD Cowen's rating cut XM
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
52%
167 → 80 words
Want the full story? Read the original article
Read on MarketWatch